Parsifal at ASCO 2016
At ASCO 2016, MedSIR presented its PARSIFAL phase II study design; a currently ongoing study that will end up enrolling more than 300 patients in over a half dozen countries. This RPH2 study compares the combination of palbociclib and fulvestrant versus palbociclib and letrozol in HR+/HER2- MBC.
